×

Steve Hill

About Steve Hill Steve is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 600 articles on the topic, interviewed over 100 of the leading researchers in the field, hosted livestream events focused on aging, as well as attending various medical industry conferences. He served as a member of the Lifespan.io board since 2017 until the org merged with SENS Research Foundation and formed the LRI. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, Swiss Monthly, Keep me Prime, and New Economy Magazine. Steve is one of three recipients of the 2020 H+ Innovator Award and shares this honour with Mirko Ranieri – Google AR and Dinorah Delfin – Immortalists Magazine. The H+ Innovator Award looks into our community and acknowledges ideas and projects that encourage social change, achieve scientific accomplishments, technological advances, philosophical and intellectual visions, author unique narratives, build fascinating artistic ventures, and develop products that bridge gaps and help us to achieve transhumanist goals. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.

Related Organizations

Articles from this author

LIN Report
This content is password protected. To view it please enter your password below: Password:
Skin aging
A recent study featured in the Journal of Cosmetic Dermatology has analyzed the impact of a topical product containing OS-01. This is a senotherapeutic peptide that targets senescence, affecting the skin's barrier function and multiple aging biomarkers [1]. Conducted by a team from OneSkin alongside academic partners, this initial trial aimed to determine if skin...
Matthew O'Connor
Recently, Cyclarity Therapeutics announced the launch of a Phase 1 human clinical trial for a drug that aims to remove the arterial plaques that lead to heart attacks and strokes. Tackling the leading cause of death worldwide Cyclarity Therapeutics is working on a cost-effective small molecule drug aimed at eliminating arterial plaque, thus potentially addressing...
Atherosclerosis
Cyclarity Therapeutics, a biotechnology company based at the Buck Institute in California, has launched its first human clinical trial. Its primary candidate cyclodextrin drug, UDP-003, focuses on 7-ketocholesterol, an oxidized cholesterol variant that builds up in cells as we age. Atherosclerosis involves the accumulation of plaque within arteries, and it primarily results from this oxidized...
Editorial
The nights are the longest of the year, the holidays are drawing near, and we are back with a festive edition of the Lifespan.io editorial. This time, we bring you some of this year's highlights and talk about what the future holds for our content. Lifespan.io and SENS Research Foundation merge Regulars will recall that...
Editorial
For those of us living in the Northern Hemisphere, the summer days are gone and the cooler days of fall have arrived. While it’s time to ditch the beachwear for chunky sweaters and a hot chocolate by the fire, things have been heating up in the longevity space. Lifespan merges with SENS Research Foundation Lifespan.io...